Headlands Technologies LLC Acquires 54,534 Shares of Boston Scientific Corporation $BSX

Headlands Technologies LLC boosted its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 239.9% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 77,266 shares of the medical equipment provider's stock after purchasing an additional 54,534 shares during the quarter. Headlands Technologies LLC's holdings in Boston Scientific were worth $3,298,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Kelleher Financial Advisors acquired a new stake in shares of Boston Scientific in the second quarter valued at approximately $25,000. FWL Investment Management LLC acquired a new position in Boston Scientific in the 2nd quarter valued at $26,000. Swiss RE Ltd. acquired a new position in Boston Scientific in the 4th quarter valued at $26,000. Garton & Associates Financial Advisors LLC bought a new stake in shares of Boston Scientific during the 4th quarter valued at $26,000. Finally, Clal Insurance Enterprises Holdings Ltd bought a new stake in shares of Boston Scientific during the 1st quarter valued at $28,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Insider Activity at Boston Scientific

In related news, Director Edward J. Ludwig bought 5,000 shares of the business's stock in a transaction on Friday, July 31st. The shares were purchased at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the transaction, the director directly owned 30,359 shares of the company's stock, valued at approximately $1,380,727.32. This represents a 19.72% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Michael F. Mahoney purchased 186,240 shares of the company's stock in a transaction dated Monday, August 3rd. The stock was purchased at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the purchase, the chief executive officer directly owned 1,590,024 shares in the company, valued at $76,845,859.92. The trade was a 13.27% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders have purchased 194,522 shares of company stock valued at $9,385,210. 0.34% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Barclays decreased their price target on Boston Scientific from $96.00 to $89.00 and set an "overweight" rating on the stock in a research report on Thursday, May 28th. Wolfe Research downgraded shares of Boston Scientific from an "outperform" rating to a "peer perform" rating in a research note on Friday, May 29th. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and issued a $60.00 target price on shares of Boston Scientific in a report on Thursday, July 30th. UBS Group dropped their target price on shares of Boston Scientific from $74.00 to $67.00 and set a "buy" rating for the company in a research report on Thursday, July 30th. Finally, Truist Financial cut their price target on shares of Boston Scientific from $62.00 to $57.00 and set a "buy" rating for the company in a report on Thursday, July 30th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $71.62.

Boston Scientific Price Performance

Shares of BSX stock opened at $46.82 on Monday. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a twelve month low of $42.20 and a twelve month high of $109.50. The company has a market cap of $67.85 billion, a P/E ratio of 18.96, a P/E/G ratio of 1.02 and a beta of 0.56. The business has a fifty day simple moving average of $46.56 and a 200 day simple moving average of $56.53.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.83 by $0.03. The firm had revenue of $5.44 billion for the quarter, compared to analysts' expectations of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business's revenue for the quarter was up 7.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, sell-side analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its Board of Directors has approved a share buyback plan on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's management believes its stock is undervalued.

Boston Scientific Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source